Serpins pp 157-182 | Cite as

Analysis of In Vivo Serpin Functions in Models of Inflammatory Vascular Disease

  • Hao Chen
  • Sriram Ambadapadi
  • Erbin Dai
  • Liying Liu
  • Jordan R. Yaron
  • Liqiang Zhang
  • Alexandra Lucas
Part of the Methods in Molecular Biology book series (MIMB, volume 1826)


Serpins have a wide range of functions in regulation of serine proteases in the thrombotic cascade and in immune responses, representing up to 2–10% of circulating proteins in the blood. Selected serpins also have cross-class inhibitory actions for cysteine proteases in inflammasome and apoptosis pathways. The arterial and venous systems transport blood throughout the mammalian body representing a central site for interactions between coagulation proteases and circulating blood cells (immune cells) and target tissues, a very extensive and complex interaction. While analysis of serpin functions in vitro in kinetics or gel shift assays or in tissue culture provides very necessary information on molecular mechanisms, the penultimate assessment of biological or physiological functions and efficacy for serpins as therapeutics requires study in vivo in whole animal models (some also consider cell culture to be an in vivo approach).

Mouse models of arterial transplant with immune rejection as well as models of inflammatory vasculitis induced by infection have been used to study the interplay between the coagulation and immune response pathways. We describe here three in vivo vasculitis models that are used to study the roles of serpins in disease and as therapeutics. The models described include (1) mouse aortic allograft transplantation, (2) human temporal artery (TA) xenograft into immunodeficient mouse aorta, and (3) mouse herpes virus (MHV68)-induced inflammatory vasculitis in interferon-gamma receptor (IFNγR) knockout mice.

Key words

Serpin Thrombosis Thrombolysis Inflammation Immune Serine protease Cysteine protease Vasculitis Virus Transplant 


  1. 1.
    Bhakuni T, Ali MF, Ahmad I et al (2016) Role of heparin and non heparin binding serpins in coagulation and angiogenesis: a complex interplay. Arch Biochem Biophys 604:128–142CrossRefPubMedGoogle Scholar
  2. 2.
    Mulder R, Croles FN, Mulder AB et al (2017) SERPINC1 gene mutations in antithrombin deficiency. Br J Haematol 178(2):279–285CrossRefPubMedGoogle Scholar
  3. 3.
    Hohensinner PJ, Baumgartner J, Kral-Pointner JB et al (2017) PAI-1 (plasminogen activator Inhibitor-1) expression renders alternatively activated human macrophages proteolytically quiescent. Arterioscler Thromb Vasc Biol 37:1913–1922CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chu AJ (2010) Blood coagulation as an intrinsic pathway for proinflammation: a mini review. Inflamm Allergy Drug Targets 9:32–44CrossRefPubMedGoogle Scholar
  5. 5.
    Esmon C (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417–430CrossRefPubMedGoogle Scholar
  6. 6.
    Lewis EC (2012) Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med 18:957–970CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Berger M, Baldwin WM 3rd, Jordan SC (2016) Potential roles for C1 inhibitor in transplantation. Transplantation 100:1415–1424CrossRefPubMedGoogle Scholar
  8. 8.
    Bagnasco SM, Kraus ES (2015) Intimal arteritis in renal allografts: new takes on an old lesion. Curr Opin Organ Transplant 20:343–347CrossRefPubMedGoogle Scholar
  9. 9.
    Halloran PF, Famulski K, Reeve J (2015) The molecular phenotypes of rejection in kidney transplant biopsies. Curr Opin Organ Transplant 20:359–367CrossRefPubMedGoogle Scholar
  10. 10.
    Comarmond C, Biard L, Lambert M et al (2017) Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136:1114–1122CrossRefPubMedGoogle Scholar
  11. 11.
    Kawasaki A, Purvin V (2009) Giant cell arteritis: an updated review. Acta Ophthalmol 87:13–32CrossRefPubMedGoogle Scholar
  12. 12.
    Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349:160–169CrossRefPubMedGoogle Scholar
  13. 13.
    Baldrighi M, Mallat Z, Li X (2017) NLRP3 inflammasome pathways in atherosclerosis. Atherosclerosis 267:127–138CrossRefPubMedGoogle Scholar
  14. 14.
    Lisman T (2017) Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res. [Epub ahead of print]
  15. 15.
    Tabas I, Lichtman AH (2017) Monocyte-macrophages and T cells in atherosclerosis. Immunity 47:621–634CrossRefPubMedGoogle Scholar
  16. 16.
    Crea F, Libby P (2017) Acute coronary syndromes: the way forward from mechanisms to precision treatment. Circulation 136:1155–1166CrossRefPubMedGoogle Scholar
  17. 17.
    Hansson GK (2017) Inflammation and atherosclerosis, the end of a controversy. Circulation 136:1875–1877CrossRefPubMedGoogle Scholar
  18. 18.
    Hoffmann JN (2006) Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 95:850–856CrossRefPubMedGoogle Scholar
  19. 19.
    Wagner JA, Langenfeld H, Klett L et al (2012) Activated protein C in patients with septic shock: a consecutive case series. Int J Clin Pharm 34:23–26CrossRefPubMedGoogle Scholar
  20. 20.
    Geisbert TW, Hensley LE, Jahrling PB et al (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362:1953–1958CrossRefPubMedGoogle Scholar
  21. 21.
    Dai E, Guan H, Liu L et al (2003) Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 278:18563–18572CrossRefPubMedGoogle Scholar
  22. 22.
    Dai E, Viswanathan K, Sun YM et al (2006) Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 281:8041–8050CrossRefPubMedGoogle Scholar
  23. 23.
    Dai E, Liu LY, Wang H et al (2010) Chemokine: glycosaminoglycan interaction is a pivotal regulatory step in transplant vascular inflammation and disease. PLoS One 5:e10510CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Viswanathan K, Bot I, Liu L et al (2012) Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro. PLoS One 7:e44694 PONE-D-11-12856R3CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ambadapadi S, Munuswamy-Ramanujam G, Zheng D et al (2016) Reactive center loop (RCL) peptides derived from serpins display independent coagulation and immune modulating activities. J Biol Chem 291(6):2874–2887 pii:jbc.M115.704841CrossRefPubMedGoogle Scholar
  26. 26.
    Miller LW, Dai E, Nash P et al (2000) Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 101:1598–1605CrossRefPubMedGoogle Scholar
  27. 27.
    Rowinska Z, Gorressen S, Merx MW et al (2017) Using the sleeve technique in a mouse model of aortic transplantation - an instructional video. J Vis Exp (128).
  28. 28.
    Munuswamy-Ramanujam G, Dai E, Liu LY et al (2010) Serpins targeting thrombolytic proteases alter T helper lymphocyte sub population. neuroserpin, a thrombolytic serine protease inhibitor (Serpin), blocks transplant vasculopathy with associated potent anti-inflammatory and anti-atherogenic activity in mouse aortic allograft transplant models. Thromb Haemos 103:545–555CrossRefGoogle Scholar
  29. 29.
    Viswanathan K, Liu L, Vaziri S et al (2006) Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. Thromb Haemost 95:499–510CrossRefPubMedGoogle Scholar
  30. 30.
    de Waard V, Arkenbout EK, Carmeliet P et al (2002) Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol 22:1978–1983CrossRefPubMedGoogle Scholar
  31. 31.
    Chen H, Zheng DH, Dai E et al (2015) Xenografts from bypass (LIMA control) and suspected Giant cell arteritis (GCA/TA) patients in SCID mice have reduced inflammation with serpin treatment. PLoS One 10:e0115482CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Weyand CM, Ma-Krupa W, Pryshchep O et al (2005) Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 1062:195–208CrossRefPubMedGoogle Scholar
  33. 33.
    Deng J, Younge BR, Olshen RA et al (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121:906–915CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Dal Canto AJ, Swanson PE, O’Guin AK et al (2011) IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 107:R15–R22CrossRefGoogle Scholar
  35. 35.
    Krug LT, Torres-González E, Qin Q et al (2010) Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis. Am J Pathol 177:608–621CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Chen H, Abbott J, Zheng D et al (2013) Myxoma virus serpin modulates protease pathways and prolongs survival in lethal herpes viral infection. Antimicrob Agents Chemother 57:4114–4127CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Feldman ER, Kara M, Coleman CB et al (2014) Virus-encoded MicroRNAs facilitate gammaherpesvirus latency and pathogenesis in vivo. MBio 5:e00981-14CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chen H, Zheng D, Davids J et al (2011) Viral serpin therapeutics from concept to clinic. Methods Enzymol 3499:301–329CrossRefGoogle Scholar
  39. 39.
    Bartee MY, Dai E, Liu L et al (2009) 10 M-T7: measuring chemokine-modulating activity. Methods Enzymol 460:209–228CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Hao Chen
    • 1
    • 2
  • Sriram Ambadapadi
    • 3
    • 4
  • Erbin Dai
    • 5
  • Liying Liu
    • 5
  • Jordan R. Yaron
    • 6
  • Liqiang Zhang
    • 3
  • Alexandra Lucas
    • 3
    • 4
  1. 1.The Department of Tumor SurgerySecond Hospital of Lanzhou UniversityLanzhouChina
  2. 2.The Key Laboratory of the Digestive System Tumors of Gansu ProvinceLanzhouChina
  3. 3.Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeUSA
  4. 4.Department of Medicine, Divisions of Cardiovascular Medicine and RheumatologyUniversity of FloridaGainesvilleUSA
  5. 5.Department of SurgeryBIDMC, Harvard Medical SchoolBostonUSA
  6. 6.Centers for Personalized Diagnostics and Immunology, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeUSA

Personalised recommendations